Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Aug;106(4):523-31.
doi: 10.1172/JCI10370.

Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice

A C Li  1 , K K Brown, M J Silvestre, T M Willson, W Palinski, C K Glass
Affiliations

Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice

A C Li et al. J Clin Invest. 2000 Aug.

Abstract

The peroxisome proliferator-activated receptor gamma (PPARgamma) is a nuclear receptor that regulates fat-cell development and glucose homeostasis and is the molecular target of a class of insulin-sensitizing agents used for the management of type 2 diabetes mellitus. PPARgamma is highly expressed in macrophage foam cells of atherosclerotic lesions and has been demonstrated in cultured macrophages to both positively and negatively regulate genes implicated in the development of atherosclerosis. We report here that the PPARgamma-specific agonists rosiglitazone and GW7845 strongly inhibited the development of atherosclerosis in LDL receptor-deficient male mice, despite increased expression of the CD36 scavenger receptor in the arterial wall. The antiatherogenic effect in male mice was correlated with improved insulin sensitivity and decreased tissue expression of TNF-alpha and gelatinase B, indicating both systemic and local actions of PPARgamma. These findings suggest that PPARgamma agonists may exert antiatherogenic effects in diabetic patients and provide impetus for efforts to develop PPARgamma ligands that separate proatherogenic activities from antidiabetic and antiatherogenic activities.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Atherosclerosis in LDLR–/– mice fed a high-fat, cholesterol-enriched Western diet for 10 weeks. (a) Sections through the aortic root at the levels of the aortic valves were stained for elastin to highlight the medial boundaries of atherosclerotic lesions. (b) Quantitative analysis of lesion areas in control mice (C), mice treated with rosiglitazone (Ro), and mice treated with GW7845 (GW). For male mice, means ± SEM were: C, 0.161 ± 0.067 mm2/section (n = 10); Ro, 0.037 ± 0.014 mm2/section (n = 12); GW, 0.063 ± 0.027 mm2/section (n = 10). For female mice, means ± SEM were: C, 0.131 ± 0.035 mm2/section (n = 10); Ro, 0.183 ± 0.0.088 mm2/section (n = 10); GW, 0.181±0.0091 mm2/section (n = 10). NS, not statistically significant.
Figure 2
Figure 2
Size distribution of lipoprotein particles in LDLR–/– mice fed a high-fat, cholesterol-enriched diet and treated with solvent (control; diamonds), rosiglitazone (squares), or GW7845 (triangles) for 10 weeks. Plasma was pooled from four mice from each treatment group and fractionated by FPLC. Mean cholesterol content in each fraction was determined in duplicate.
Figure 3
Figure 3
Glucose and insulin responses to an oral glucose challenge in LDLR–/– mice fed the normal chow (circles); high-fat, cholesterol-enriched diet and solvent (control; diamonds); rosiglitazone (squares); or GW7845 (triangles). Blood glucose and plasma insulin levels were determined at base line (after a 4-hour fast) and 15, 30, 60, and 90 minutes after oral administration of 0.75 mg glucose/g body weight. Samples were taken from eight animals per group. Data are expressed as the mean ± SEM. AP < 0.0001, BP < 0.002, CP < 0.015, and DP < 0.04, drug treatment group vs. control group.
Figure 4
Figure 4
Expression of TNF-α, MCP-1, VCAM-1, and gelatinase B mRNA in the aortic root. The mRNA levels were quantitated using real-time RT-PCR. Six to seven samples per group were analyzed. C, control; Ro, rosiglitazone; GW, GW7845. Data are expressed as mean ± SEM. AP < 0.05, BP < 0.01, and CP < 0.001, drug treatment groups vs. cholesterol group.
Figure 5
Figure 5
Expression of macrosialin, CD36, SR-A, MCP-1, TNF-α, and VCAM-1 mRNA in the aorta. Male LDLR–/– mice were fed either a normal chow diet (N) or a high-cholesterol diet for 4 months to induce the development of atherosclerosis (Athero). Animals fed the high-cholesterol diet were then treated with either solvent control, rosiglitazone, or GW8745 for 2 weeks. The mRNA levels were quantitated using real-time RT-PCR. Data represent pooled aortas with an average weight of 3.86 ± 0.16 mg/aorta for normal chow (N) (n = 11); 5.75 ± 0.67 mg/aorta for high cholesterol (C)(n = 6); 5.67 ± 0.56 mg/aorta for high cholesterol/rosiglitazone (Ro) (n = 6); and 5.80 ± 0.70 mg/aorta for high cholesterol/GW7845 (GW) (n = 6). Data are in triplicates and expressed as mean ± SEM.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kannel W, McGee D. Diabetes and cardiovascular disease: the Framingham study. JAMA. 1979;241:2035–2038. - PubMed
    1. Uusitupa M, Niskanen L, Siitonen O. 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin levels, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation. 1990;82:27–36. - PubMed
    1. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915–924. - PubMed
    1. Napoli C, et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest. 1997;100:2680–2690. - PMC - PubMed
    1. Kodama T, Reddy P, Kishimoto C, Krieger M. Purification and characterization of a bovine acetyl low density lipoprotein receptor. Proc Natl Acad Sci USA. 1988;85:9238–9242. - PMC - PubMed

Publication types

MeSH terms

Substances